Supernus Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
52.21 M |
Public Float |
43.14 M |
Supernus Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.9 |
Market Cap |
$1.71 B |
Shares Outstanding |
52.38 M |
Public Float |
50.58 M |
Address |
1550 East Gude Drive Rockville Maryland 20850 United States |
Employees | - |
Website | http://www.supernus.com |
Updated | 07/08/2019 |
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. |